Nivo-lution in Mesothelioma.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 31315884.
- Also identified by DOI 10.1158/1078-0432.CCR-19-1836 and PMC identifier 6744981.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The MERIT study was a single-arm, phase II clinical trial of nivolumab for the second- or third-line treatment of patients with malignant pleural mesothelioma in Japan. MERIT confirmed that PD-1 inhibition has activity in mesothelioma and led to the regulatory approval of nivolumab for the treatment of mesothelioma in Japan.<i>See related article by Okada et al., p. 5485</i>.
Medical subject headings
- Lung Neoplasms
- Mesothelioma